CD89 靶点蛋白|抗体药物|临床药物信息 - ACROBiosystems中国

> 【CD89】

CD89信息

英文名称：IgA Fc receptor
中文名称：免疫球蛋白αFc受体
靶点别称：Fc Fragment Of IgA Receptor，Fc Fragment Of IgA， Receptor For，Fc Alpha Receptor，FCAR Variant 14，IgA Fc Receptor，CD89 Antigen，CTB-61M7.2，FcalphaRI，Immunoglobulin alpha Fc receptor，CD89，FCAR

上市药物数量：0
临床药物数量：1
最高研发阶段：临床一期

CD89产品列表

筛选结果

产品库

在线 (1)

物种

Human (1)

标签

His Tag (1)

属性

Protein (1)

标记

Unconjugated (1)

货号	物种	产品描述	蛋白结构	纯度	活性
CD9-H52Ha	Human	Human CD89 / FCAR Protein, His Tag (MALS verified)

ACRO质量管理体系

评论(0)

CD89分子别名

CD89,FCAR,IgA Fc receptor

CD89分子背景

B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

CD89临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
JJP-1212	JJP-1212; JJP1212	临床一期	Jjp Biologics Sp. z o.o.	线性IgA大疱性皮肤病	详情

扫一扫关注微信公众号获取ACRO最新资讯

ACROBiosystems百普赛斯生物科技股份有限公司

全国：+86 400-682-2521

北京：010-53681107

上海：021-50850665

海外：+1 800-810-0816

邮箱：（产品订购）order.cn@acrobiosystems.com

邮箱：（技术支持）tech.cn@acrobiosystems.com

邮箱：（廉洁合规）lianjie@acrobiosystems.com

地址：北京经济技术开发区宏达北路8号5号楼4层

在线留言

发送

消息提示

请输入您的联系方式,再点击提交！